Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect.
Simple Summary: This study explores the efficacy and safety of alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) regimens in patients with metastatic pancreatic cancer (MPC). The approach aims to reduce toxicity, slow resistant cancer biology, and facilitate the in...
| Publicado en: | Cancers Vol. 15; no. 23; pp. 5588 - 5598 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Dec2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |